ArticleFrontiers in oncology2026
Development of a second primary tumor during maintenance immunotherapy in metastatic gingival squamous cell carcinoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple primary tumors are defined as two or more distinct malignancies occurring simultaneously or metachronously in the same patient. This report describes a patient with extensively metastatic gingival squamous cell carcinoma who achieved radiologic complete remission (CR) through combined immunotherapy, chemotherapy, and local radiotherapy. The patient continued immunotherapy maintenance for 38 months. Two years after CR, a second primary tumor emerged. The second tumor was surgically resected, followed by postoperative maintenance therapy with oral Tegafur-Gimeracil-Oteracil (S-1) capsules. As of the last follow-up on January 14, 2025, nearly two years after the second surgery, the patient showed no local recurrence or distant metastasis. This case suggests that while immunotherapy provided excellent overall tumor control, it failed to prevent the occurrence of the second primary tumor. Whether prolonged immunotherapy (38 months vs. the standard 24 months) positively impacts patient prognosis requires further exploration. This case highlights that even after achieving CR with immunotherapy, vigilance for the development of second primary tumors during maintenance therapy is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.